Germany Scraps Variable Drug Discount Plan After Industry Backlash

The original proposal sought to tie price cuts to fluctuating healthcare revenues and national spending levels. Executives balked at the uncertainty, with Eli Lilly’s leadership threatening to halve a planned 2.3-billion-euro investment in the country. By moving to a fixed structure, Berlin aims to provide the predictability required for long-term manufacturing commitments.

The federal health ministry remains cautious, stating that no final decisions have been reached regarding the legislative overhaul. While the VFA industry association welcomed the shift in tone, they continue to press for a rigorous impact assessment before any new fiscal measures are locked into law. The government’s broader goal remains closing a 20-billion-euro funding gap to avoid raising mandatory health insurance premiums.